Morbidity of Anogenital Disease

Types of HPV demonstrate a high degree of site specificity, with some HPV types only found on certain parts of the skin or mucous membranes. The overall prevalence of HPV in women is 22-35%. In men, the prevalence is 2-35% depending on the sexual practices of the population being studied.

HPV infection alone does not cause malignant transformation of infected tissue. Cofactors, such as tobacco use, ultraviolet radiation, pregnancy, folate deficiency, and immune suppression, have been implicated in this process. Patients receiving immunosuppressive drugs and patients with defects in cell-mediated immunity, including those infected with HIV are especially susceptible to developing HPV infections.

A direct correlation exists between anogenital HPV infection and measures of sexual activity, such as the age of first intercourse and the lifetime number of sexual partners. The prevalence of anogenital mucosal HPV infections is highest among college-aged women and men. The incidence of high-risk HPV infections drops after age 20-24 years, and the incidence of low-risk HPV types plateaus after age 30-39 years.

Women with a history of a cervical high-grade squamous intraepithelial lesion (HGSIL) or invasive squamous cell carcinoma (SCC) of the cervix are at increased risk for subsequent development of invasive cancer in other tissues of the anogenital/mucosal category, particularly vaginal and anal carcinoma. In these patients, the relative risk of vaginal carcinoma is 5.6, and the risk of anal carcinoma is 4.

Anal cancer has been strongly associated with male homosexuality and specific male practices, such as engaging in receptive anal intercourse. Relative risk is 33. However, the overall disease prevalence is higher in women than in men, with a female-to-male ratio of 1.5:1.

Patients who are immunosuppressed, particularly those with cutaneous malignant lesions, have a much higher incidence of EV-HPV infection than the general population. These lesions can undergo malignant transformation. Ten percent of patients with EV originate from consanguineous marriages, suggesting an autosomal recessive mode of inheritance.

Nongenital cutaneous warts are more common among teenagers and adults who work as meat, poultry, and fish handlers. The incidence approaches 10% in child and young adult populations. However, nongenital cutaneous warts rarely occur in people younger than 5 years and usually regress within 2 years. EV develops at an average age of onset of 6 years, and, beginning in the fourth decade of life, the lesions can undergo malignant transformation into invasive SCC.

Most doctors use cauterization or freezing as a first option to cure Genital Warts. Unfortunately, success achieved with this method is often temporary and the warts soon reappear. For Genital Warts, cures may involve having to surgically excise or burn them off. After surgical intervention or chemical acids are used, one can expect a scar in that area.

Surgical intervention as a HPV cure attempts not only to cut out the virus but also to stimulate tissue inflammation. The theory is that the body will then develop an antibody response to prevent viral recurrence. However, this method to cure Genital Warts often fails as doctors are unable to remove the virus in its entirety, since it commonly lodges itself deep in the dermal layers of the skin.

As the virus is microscopic and particles under the skin are not visible, doctors cannot possibly be certain if they have effected complete HPV cures by removing all viral microparticles. Among all the types of genital warts cures, genital surgery subjects the patient to a highly invasive procedure. This method can be most unpleasant and ineffective, and can also create genital scarring.

An alternative antiviral treatment is now available which represents a very promising solution to the growing epidemic of genital warts. HPVCurative is a new, highly effective and potent way to cure genital warts. It is valued for its role in the realm of genital warts cures, and has provided total clearance of the infection time after time.

Users of HPVCurative experience rapid elimination of genital warts without scarring or recurrence. The treatment is painless and provides superb results when compare to other HPV cures. It eliminates genital warts and restores skin tissue to the state it was in prior to the infection. Since the treatment can effectively remove genital warts and wart-like substances on the genitals, acid or surgical HPV cures may soon become a thing of the past.

HPVCurative has powerful medicinal properties that give it an amazing ability to reduce tumor growths resulting from HPV. The organic extracts in this treatment also stimulate immune functionality, thereby strengthening the immune system. To learn more, please go to http://www.bcured.net.